Wegovy Results UK: Expected Weight Loss, Timelines & What the Clinical Data Shows

Wegovy (semaglutide 2.4mg) entered the UK market supported by one of the most robust evidence bases for any weight management medication. The STEP (Semaglutide Treatment Effect in People with Obesity) programme comprised multiple phase 3 trials, each examining semaglutide's efficacy in different patient populations.

Key STEP trial results:

STEP 1 (adults with obesity, no type 2 diabetes, 68 weeks): - Average weight loss: 14.9% of body weight on semaglutide vs 2.4% on placebo - 86% of semaglutide participants achieved ≥5% weight loss - 69% achieved ≥10% weight loss - 50% achieved ≥15% weight loss

STEP 2 (adults with type 2 diabetes, 68 weeks): - Average weight loss: 9.6% — lower than in non-diabetic patients, reflecting the metabolic impact of type 2 diabetes on weight loss response

STEP 3 (intensive behavioural therapy added): - Average weight loss: 16% — reinforcing the importance of lifestyle support alongside medication

STEP 4 (sustained weight loss study): - Participants who continued semaglutide maintained most of their weight loss; those switched to placebo regained approximately two-thirds of lost weight — highlighting the chronic nature of obesity as a condition requiring ongoing treatment

SELECT trial (cardiovascular outcomes, 2023): - Semaglutide 2.4mg reduced major adverse cardiovascular events (MACE) by 20% in adults with established cardiovascular disease and overweight/obesity — a landmark finding that extended Wegovy's UK licensing to include cardiovascular risk reduction

*This article is for educational purposes only and does not constitute medical advice. Always consult your prescribing clinician before making treatment decisions.*

Wegovy is initiated at a low dose and escalated gradually over 16 weeks to the therapeutic maintenance dose of 2.4mg. Understanding this escalation journey helps set realistic expectations for the pace of weight loss.

Weeks 1–4 (0.25mg): - Starting dose — primarily for tolerability, not weight loss - Most patients experience reduced appetite almost immediately - Weight loss is modest: typically 1–3% of body weight - Common early side effects: mild nausea, constipation, reduced appetite

Weeks 5–8 (0.5mg): - Appetite suppression becomes more consistent - Cumulative weight loss: approximately 3–5% for most patients

Weeks 9–12 (1mg): - Mid-escalation — weight loss accelerates - Many patients begin noticing meaningful changes in clothing fit and energy levels

Weeks 13–16 (1.7mg): - Near-maintenance dose — results continue to compound

Week 17+ (2.4mg maintenance): - Full therapeutic dose; most clinical trial weight loss data is measured from this point forward at 68 weeks total - By month 6 (including escalation): average of 8–11% body weight loss in real-world UK data - By month 12: average of 12–15%, with motivated adherent patients potentially reaching 17–18% - By month 18 (68 weeks — STEP 1 endpoint): average 14.9% in trial, with top quartile responders exceeding 20%

*Timeline estimates are based on STEP trial data and published real-world analyses. Individual results vary considerably.*

One of the most common concerns among UK Wegovy users is the weight loss plateau — a period where the scale stops moving despite continued medication use and lifestyle effort. Understanding why this happens and what to do about it is critical to long-term success.

Why plateaus occur on semaglutide: - The body actively resists weight loss through adaptive thermogenesis — metabolic rate slows as body weight decreases - As body weight falls, total daily energy expenditure decreases (you are simply moving a smaller body) - Appetite, while suppressed by semaglutide, may partially recover over time as the body adapts - Dietary drift — subtle increases in calorie intake that accumulate over months

When to expect a plateau: - Most patients experience a significant slowing of weight loss between 6–12 months on maintenance dose - A plateau is generally defined as fewer than 0.5% body weight change over 4–6 weeks despite adherence

Strategies to address the plateau:

• •Re-audit your diet — work with a dietitian to recalibrate calorie targets based on your new lower body weight
• •Increase protein intake — prioritising 1.2–1.6g/kg body weight helps preserve muscle and maintain satiety
• •Add or intensify resistance training — building muscle mass counteracts adaptive thermogenesis
• •Review your sleep — poor sleep elevates ghrelin (hunger hormone) and undermines medication effectiveness
• •Discuss with your prescriber — if you are not at maximum dose (2.4mg), escalation may be appropriate; alternatively, switching to tirzepatide may be considered in some clinical contexts

*Plateaus are a normal physiological response to weight loss, not a sign of treatment failure. Discuss any concerns with your prescribing clinician.*

The STEP 4 trial delivered an important finding that all UK Wegovy patients should understand: stopping semaglutide results in significant weight regain. In STEP 4, participants who switched from semaglutide to placebo regained approximately two-thirds of their lost weight within 12 months.

This reflects the biology of obesity, not a personal failing. Semaglutide addresses dysregulated appetite and energy regulation — mechanisms that do not permanently correct themselves after a course of treatment, in the same way that blood pressure medication must be continued long-term.

What this means for UK patients: - Long-term prescribing is likely to be necessary for sustained benefit - NHS guidance, following NICE TA875, allows for continued prescribing where weight management service review confirms ongoing clinical benefit - Private prescribers should include a long-term maintenance plan in any treatment agreement

Maximising sustained results: - Build behavioural habits during the active weight loss phase (regular exercise, structured eating patterns, mindful eating) so they continue to support maintenance when the rate of loss slows - Engage with a dietitian or weight management psychologist to address emotional eating patterns or behavioural drivers of weight gain - Keep regular clinical reviews — monitoring blood pressure, HbA1c, lipids, and weight ensures the full metabolic benefit of weight loss is tracked - Understand that some weight regain after achieving lowest weight is biologically normal and does not mean the medication is failing

Transitioning off Wegovy: For patients who wish to or are required to stop treatment, a gradual tapering approach (rather than sudden cessation) is generally recommended to manage the rate of any rebound. Discuss this explicitly with your prescriber.

Contextualising Wegovy's results within the broader landscape of UK weight management options helps patients and clinicians make well-informed treatment decisions.

UK weight management options and typical weight loss:

| Treatment | Typical Weight Loss | Route | Frequency | |---|---|---|---| | Lifestyle only (diet + exercise) | 3–8% sustained | Non-pharmacological | Ongoing | | Orlistat | 3–5% vs placebo | Oral capsule | 3x daily | | Saxenda (liraglutide 3mg) | 6–8% vs placebo | Subcutaneous injection | Daily | | Wegovy (semaglutide 2.4mg) | ~14–15% vs placebo | Subcutaneous injection | Weekly | | Mounjaro (tirzepatide 15mg) | ~20–22% vs placebo | Subcutaneous injection | Weekly | | Bariatric surgery (sleeve/bypass) | 25–35% | Surgical | One-time |

Key takeaways: - Wegovy represents a step-change in non-surgical weight management compared to older options - Mounjaro (tirzepatide) achieves meaningfully greater weight loss than Wegovy in head-to-head comparisons (SURMOUNT-5 trial) - The choice between Wegovy and Mounjaro should be guided by clinical profile, contraindications, tolerability, and cost — not weight loss potential alone - For patients with established cardiovascular disease, Wegovy has a specific cardiovascular indication (SELECT trial data) that Mounjaro does not yet have in the UK to the same extent

*This comparison is for informational purposes only. Treatment selection should be made in consultation with a qualified UK prescribing clinician who can assess your individual circumstances.*